15.35  -0.21 (-1.35%)		05-23 16:00
Open: 15.56 High: 17.88 Volume: 4,701,612		Pre. Close: 15.56 Low: 15.02 Market Cap: 1,312(M)

Short term
Mid term
Targets	6-month :	19.74	1-year :	22.65
Resists	First :	16.9	Second :	19.39
Pivot price	16.53
Supports	First :	12.85	Second :	10.69
MAs	MA(5) :	16.32	MA(20) :	15.97
	MA(100) :	14.64	MA(250) :	12.6
MACD	MACD :	0.5	Signal :	0.7
%K %D	K(14,3) :	29	D(3) :	44.5
RSI	RSI(14): 47.2
52-week	High :	19.39	Low :	8.26

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ LQDA ] has closed above bottom band by 27.8%. Bollinger Bands are 75.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	18 - 18.17	18.17 - 18.27
Low:	14.7 - 14.9	14.9 - 15.02
Close:	15.12 - 15.44	15.44 - 15.64

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Sat, 24 May 2025
FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute - Yahoo

Fri, 23 May 2025
FDA Approves Liquidia's (LQDA) Yutrepia, Court Ruling Pending - GuruFocus

Fri, 23 May 2025
Liquidia's Yutrepia gets FDA approval for added indication - Seeking Alpha

Fri, 23 May 2025
Liquidia (LQDA) Trading Resumes After Brief Halt | LQDA Stock Ne - GuruFocus

Fri, 23 May 2025
Trading Halted for Liquidia (LQDA) as Anticipated News Awaits | - GuruFocus

Fri, 23 May 2025
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	85 (M)
Held by Insiders	6.625e+007 (%)
Held by Institutions	13.4 (%)
Shares Short	12,070 (K)
Shares Short P.Month	0 (K)

EPS	-1.197e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	237.8 %
Return on Equity (ttm)	-43.5 %
Qtrly Rev. Growth	1.4e+007 %
Gross Profit (p.s.)	-148.34
Sales Per Share	-872.3
EBITDA (p.s.)	3.38333e+007
Qtrly Earnings Growth	-1.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-93 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.02
Price to Cash Flow	4.04

Dividend	0
Forward Dividend	1.315e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.